ABSTRACT
Objective To study the efficacy of trimetazidine combined with perindopril in treating congestive heart failure (CHF). Methods One hundred and eighteen patients with CHF were randomly divided into experimental group and control group. All patients were given conventional medical treatment. Patients in the control group was treated with additionally with perindopril. The initial dose was 2 mg/d, and gradually increased to target dose of 4 mg/d. The experimental group was additionally treated with trimetazidine 20 mg orally 3 times a day for 12 weeks based on the regimen in the control group. The changes of left ventricular ejection fraction ( LVEF) , left ventricular end of diastolic volume ( LVEDV) , left ventricular end of systolic volume ( LVESV), stroke volume (SV),cardiac output (CO)and cardiac function (NYHA) were observed. Results In the experiment group, after treatment,LVEF,LVEDV,LVESV,CO and SV were(46. 89 ±8. 00)% ,(129. 20 ±25. 00)ml, (70.90 ±32. 00)ml, (4. 32 ±0. 65 ) L/min and (55. 06 ± 13. 27) ml, respectively, which were significantly improved compared to those before treatment (29.60 ± 11. 00)% ,(164. 40 ± 31. 00) ml, (95. 60 ± 33. 00) ml, (2.91 ±0.56) L/min and (37. 69 ± 13. 62) ml .respectively) ( P < 0.01 or P < 0. 05). After treatment, the LVEF, LVEDV, LVESV, CO and SV were (46.89 ± 8. 00)% , (34. 70 ± 9. 00)% ,( 129. 20 ± 25. 00) ml, ( 148. 20 ±29. 00) ml and (70.90 ± 32. 00)ml in the experiment group, respectively, which were significantly higher than those in the control group (81. 10 ±31.00)ml, (4. 32 ±0.65) L/min, (3. 14 ±0.60) L/min, (55. 06 ±13.27 )ml and (49. 56 ± 14. 29) ml, respectively) (P <0. 01 or P <0. 05). The overall effective rate in the experiment group was 93. 2% .which was significantly higher than that in the control group (66. 1% ) ( P < 0.01). No obvious adverse effect was observed. Conclusions The effect of trimetazidine combined with perindopril in treating congestive heart failure is satisfactory. It is safe and effective for CHF.
ABSTRACT
Objective One hypothesis is that patients with uraemia showing hyporesponsiveness to rHuEPO may have enhanced levels of immune activation causing increased rdease of inflammatory cytokines. To study the effects of chronic inflammation on the hyporesponsiveness to rHuEPO and its possible mechanisms, T cell phenotypes using flow cytometry and the relationship between these changes were detected. Methods 40 patients with MHD and 20 age-matched healthy volunteers were enrolled in the study. The MHD patients were divided into two groups according to the responsiveness to rHuEPO:22 cases with good responders and 18 cases with poor responders. The percentages of T cell subsets including CD+4 ,CD+8,CD+4/CD+28,CD+8/CD+28 T cell using flow cytometry were detected. Results The percentages of CD+4 and CD+8 T cell were lower in MHD patients than that in control group. The percentages of CD4+/CD+28 and CD+8/CD+28 T cell were lower in group of poor responders than in good responders.Conclusion Chronic inflammation state is common in MIlD patients. The percentages of CD+4/CD+28 and CD+8/CD+28 T cell in poor responders were much lower than good responders. The changes of T cell phenotypes may play a role in pathogenesis of hyporespousiveness to rHuEPO.